The European Hematology Association (EHA)

Research

SWG Educational Activities

EHA2023 Hybrid Congress

Date and location

June 8–11, 2023, in Frankfurt, Germany.

Chair

Marie Jose Kersten

Case discussions

  • Follicular Lymphoma: Martin Dreylng, Daphne De Jong.
  • Double hit Lymphoma: Andrew Davies, Elias Campo.
  • T-follicular helper cell lymphoma: Andrew Davies, Daphne De Jong.

EHA Lymphoma Group Annual Meeting

Date and location

15-16 October, 2023, in Dubrovnik, Croatia.

Chairs

  • Marie José Kersten
  • Igor Aurer

Attendance and activities

Twenty-nine delegates from fourteen countries participated.

Current and new projects were discussed.

Clinical trials promoted by or involving the SWG

Dr Nijland—Elderly study in DLBCL.

Collaborations on international projects promoted by or involving the SWG

  • Applying the simplified geriatric assessment to treatment of DLBCL and HL—collaboration with the Fondazione Italiana Linfomi (Merli, Luminari et al).
  • LUPIAE prospective registry in relapsed and refractory FL, developed by the EHA LyG and delivered in collaboration with 11 countries in Europe and the UK (Tonino et al)
  • International T cell project 2.0 (TCP2.0) and sub-studies (DANTE, Virtual Review, MATURE and PET). Developed by the EHA LyG and delivered in collaboration with eight countries in Europe, US, South America, and India (Skrypets, Federico, Luminari, Stepanishyna, Manni, Ahearne, Gru, Lückemeier et al).
  • HIV lymphoma registry (NCT05231135) and international guidelines developed by an EHA LyG-ESMO collaboration involving six countries in Europe and the UK (Hentrich et al).
  • PET in MZL (PIMENTO study), a FIL/IELSG/French study delivered in partnership with the EHA LyG across three European countries (Luminari et al).
  • The Burkitt Lymphoma Network, an international consortium established 2022 (Chamuleau et al).

Translational work promoted by or involving the SWG

  • DANTE (Dynamic Assessment of circulating tumor DNA in T-cell Lymphoma), an international T cell project 2.0 sub-study (Ahearne et al)
  • PET evaluation in PTCLs and its prognostic role: an international multicenter analysis by the TCP2.0 (Luminari et al)
  • FIL_ELDHL (Prospective study on elderly (≥ 65 years) patients affected with classical Hodgkin Lymphoma undergoing Comprehensive Geriatric Assessment at diagnosis). Embedded translational research validating the prognostic role of PET2, evaluating TMA biomarkers and assessing the role of immune senescence.